- 2 updates
A cancer patient from Essex has attacked a decision not to fund a new life-prolonging drug on the NHS - because it's too expensive.
Kim Mawby was told she only had six months to live three years ago when she discovered her breast cancer had spread. After being taken onto a trial for Kadcyla, she saw amazing results.
The National Institute for Health and Clinical Excellence or NICE hasannounced it would not fund the drug.
A mother from Essex whose life has been extended thanks to a new cancer drug has criticised the news it's to be blocked by a health watchdog.
Kim Mawby from Nazeing in Essex was told three years ago she had 6 months to live. Her breast cancer had spread to the chest wall and lung.
The mum of two was accepted onto a trial for the drug Kadcyla. After just nine weeks on the medication she went for a scan at the Royal Marsden Hospital in London.
The National Institute for Clinical Excellence has announced it would not supply the drug on the NHS because £90,000 per patient per year, it is too expensive.
Kadcyla's manufacturer Roche says it's already reduced the price and other European countries have no problem funding it.